Edward Esber, MD
Gastroenterology · Akron, OHNPI 1356332332
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Pfizer accounts for 78.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $5,742 and has fallen 99.6% since, to $22 in 2025.
Across 59 payments — averaging $125.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Boston Scientific$421
- Takeda Pharmaceuticals U.S.A., Inc.$270
- AbbVie$192
- Johnson & Johnson$138
- Phathom Pharmaceuticals, Inc.$132
- plus $418 from 11 others
What the payments were for
- Consulting fees$4,41060%
- Speaking & faculty fees$1502%
- Travel & lodging$1,40519%
- Food & beverage$1,34318%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $5,803 |
| Boston Scientific | 5 | $421 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $270 |
| AbbVie | 8 | $192 |
| Johnson & Johnson | 5 | $138 |
| Phathom Pharmaceuticals, Inc. | 1 | $132 |
| Sanofi | 1 | $120 |
| QOL Medical, LLC | 3 | $65 |
| Merck | 4 | $62 |
| Amgen | 2 | $35 |
| Bristol Myers Squibb | 2 | $34 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,375 in reported general payments places this provider in the 70th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SutabSod Sulf/Pot Chloride/Mag Sulf | 43 | $6,754 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 48 | $3,149 |
| Pantoprazole Sodium | 70 | $1,087 |
| Omeprazole | 47 | $392 |
| Famotidine | 13 | $234 |
| Ondansetron Hcl | 148 | $141 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Akron
- Ganesh VeerappanAkron$188K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.